JP2009084270A5 - - Google Patents

Download PDF

Info

Publication number
JP2009084270A5
JP2009084270A5 JP2008225403A JP2008225403A JP2009084270A5 JP 2009084270 A5 JP2009084270 A5 JP 2009084270A5 JP 2008225403 A JP2008225403 A JP 2008225403A JP 2008225403 A JP2008225403 A JP 2008225403A JP 2009084270 A5 JP2009084270 A5 JP 2009084270A5
Authority
JP
Japan
Prior art keywords
xinafoate
xinafoate salt
disease
indicated
dry powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008225403A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009084270A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2009084270A publication Critical patent/JP2009084270A/ja
Publication of JP2009084270A5 publication Critical patent/JP2009084270A5/ja
Pending legal-status Critical Current

Links

JP2008225403A 2007-09-05 2008-09-03 塩形態 Pending JP2009084270A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97003007P 2007-09-05 2007-09-05

Publications (2)

Publication Number Publication Date
JP2009084270A JP2009084270A (ja) 2009-04-23
JP2009084270A5 true JP2009084270A5 (https=) 2011-10-06

Family

ID=40293576

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008225403A Pending JP2009084270A (ja) 2007-09-05 2008-09-03 塩形態

Country Status (17)

Country Link
US (3) US8193181B2 (https=)
EP (1) EP2215087B1 (https=)
JP (1) JP2009084270A (https=)
KR (2) KR20120120453A (https=)
CN (1) CN101861314B (https=)
AR (1) AR068369A1 (https=)
AU (1) AU2008294473B2 (https=)
BR (1) BRPI0816278A2 (https=)
CA (1) CA2697495C (https=)
ES (1) ES2452965T3 (https=)
IL (1) IL203973A (https=)
MX (1) MX2010002518A (https=)
NZ (1) NZ583582A (https=)
RU (1) RU2458925C2 (https=)
TW (1) TWI371277B (https=)
WO (1) WO2009031011A2 (https=)
ZA (1) ZA201002356B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482233A (zh) 2009-05-21 2012-05-30 阿斯利康(瑞典)有限公司 新颖的嘧啶衍生物和它们在治疗癌症和其它疾病中的用途
GB0908772D0 (en) * 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
MX2013013090A (es) 2011-05-10 2013-12-16 Merck Sharp & Dohme Aminopirimidinas como inhibidores de tirosina cinaza del bazo.
US9145391B2 (en) 2011-05-10 2015-09-29 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as Syk inhibitors
EP2707357B1 (en) 2011-05-10 2017-01-18 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as syk inhibitors
WO2013052393A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
WO2013052391A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. PHENYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2763976B1 (en) 2011-10-05 2016-05-18 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
EP2768480A1 (en) * 2011-10-21 2014-08-27 Rigel Pharmaceuticals, Inc. Method and device for administering xinafoate salt of n4-(2,2-difluoro-4h-benzo [1,4]oxazin-3-one) -6-yl]-5-fluoro-n2- [3- (methylaminocarbonylmethyleneoxy) phenyl]2,4-pyrimidinediamine
EP2863914B1 (en) 2012-06-20 2018-10-03 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as syk inhibitors
US9487504B2 (en) 2012-06-20 2016-11-08 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
EP2863916B1 (en) 2012-06-22 2018-07-18 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (syk) inhibitors
EP2863915B1 (en) 2012-06-22 2017-12-06 Merck Sharp & Dohme Corp. SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2884982B1 (en) 2012-08-20 2017-09-20 Merck Sharp & Dohme Corp. SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2900665B1 (en) 2012-09-28 2018-01-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
WO2014093191A1 (en) 2012-12-12 2014-06-19 Merck Sharp & Dohme Corp. AMINO-PYRIMIDINE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2934525B1 (en) 2012-12-21 2019-05-08 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
AU2014236938B2 (en) * 2013-03-14 2018-12-20 Allergan, Inc. Composition of a sustained-release delivery and method of stabilizing proteins during fabrication process
EP2988744A4 (en) 2013-04-26 2016-11-02 Merck Sharp & Dohme THIAZOLSUBSTITUTED AMINOHETEROARYLE AS MILZTYROSINKINASE INHIBITOR
EP2988749B1 (en) 2013-04-26 2019-08-14 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
EP3083560B1 (en) 2013-12-20 2021-10-27 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9783531B2 (en) 2013-12-20 2017-10-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9822107B2 (en) 2013-12-20 2017-11-21 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015138273A1 (en) 2014-03-13 2015-09-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
WO2018189566A1 (en) * 2017-04-10 2018-10-18 Dorian Bevec Use of a chemical compound as a therapeutic agent
SG11202100240RA (en) * 2018-07-18 2021-02-25 Astrazeneca Ab A xinafoate salt of a jak inhibiting compound
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB9808802D0 (en) * 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
CA2500922A1 (en) * 2002-10-04 2004-04-22 Pharmacia Corporation Pharmaceutical compositions for treatment of parkinson's disease
BRPI0413018B8 (pt) * 2003-07-30 2021-05-25 Rigel Pharmaceuticals Inc composto, e, uso de um composto
NZ564697A (en) * 2005-06-15 2010-04-30 Boehringer Ingelheim Int Process for preparing tiotropium salts, tiotropium salts as such and pharmaceutical compositions thereof
MY150468A (en) * 2006-06-30 2014-01-30 Novartis Ag Quinolinone derivatives and their pharmaceutical compositions

Similar Documents

Publication Publication Date Title
JP2009084270A5 (https=)
CA2697495A1 (en) Xinafoate salt of n4-[(2,2-difluoro-4h-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-n2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine
AU2014219283C1 (en) Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
CN101260112B (zh) 含噻吩并[3.2-c]吡啶的乙酰肼衍生物及其制备方法和用途
ES2437346T3 (es) Procedimiento para la producción de derivado de diamina
CN103102348B (zh) 噁二唑类化合物及其制备方法、药物组合物及其用途
TW200528097A (en) Novel thiazolidin-4-one derivatives
JP2006517572A5 (https=)
CN104039765B (zh) 多奈哌齐双羟萘酸盐、制备方法及其应用
KR101823451B1 (ko) 퀴논계 화합물, 이의 광학 이성질체 및 이의 제조 방법과 의약 용도
JP2017538676A (ja) ミトコンドリア透過性遷移孔(mtPTP)の小分子阻害剤
JP2015508092A5 (https=)
BRPI0612266A2 (pt) composição fermacêutica, e, uso da mesma
JP2007522162A5 (https=)
WO2010103312A1 (en) Hydroxymorpholiness and their use for the treatment of inflammatory disorders and pain
CN116947756B (zh) 环丁烯二酮基喹啉类化合物及其制备方法、药物组合物和应用
HU229137B1 (en) 8,8a-dihydro-indeno[1,2-d]thiazole derivatives having sulphoneamid- or sulphone substitutents in the 2 position, method for production thereof and use thereof as a medicament
TWI423972B (zh) 治療呼吸系融合細胞病毒感染之多環劑
KR20140003379A (ko) 스핑고신 1-포스페이트(s1p) 수용체들에 대한 리간드들로서의 5-(바이페닐-4-일)-3-페닐-1,2,4-옥사디아졸릴 유도체들
ES2672777T3 (es) Métodos de tratamiento de estados con mediación alfa-adrenérgica
JP2007518798A5 (https=)
JP2008520611A5 (https=)
JP2015504913A (ja) 安定な非晶質のラルテグラビルカリウムプレミックス、及び、その調製方法
ES2707362T3 (es) 6-nitro-2,3-dihidroimidazo [2,1-b] oxazoles y un procedimiento de preparación de los mismos
JP2013544832A (ja) スフィンゴシン−1−リン酸(s1p)受容体モジュレーターとしての新規オキサジアゾール誘導体